Patient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period
Patients who have >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period are not eligible
Patient has ? grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period
Grade 2 peripheral neuropathy or higher or grade 1 with pain on clinical examination during the screening period
Patient has >= grade 2 peripheral neuropathy or neuropathy with pain, regardless of grade that is seen on clinical examination during the screening period
Patient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period
Patient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period
Patient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period
Peripheral neuropathy >= grade 3 on clinical examination or grade 2 with pain during the screening period
Peripheral neuropathy ? grade 3 on clinical examination or grade 2 with pain during the screening period
Peripheral neuropathy > grade 2 or > grade 1 with pain on clinical examination during the screening period
Patient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period
Patient has >= grade 2 peripheral neuropathy, or grade 1 with pain on clinical examination during the screening period
Peripheral neuropathy Grade 1 with pain or Grade 2 or higher peripheral neuropathy of any cause on clinical examination during the Screening period.
Peripheral neuropathy >= grade 2 on clinical examination or grade 1 with pain during the screening period
Patient has greater than or equal than grade 2 peripheral neuropathy, or grade 1 with pain on clinical examination during the screening period
Patient has >= grade 2 peripheral neuropathy on clinical examination during the screening period
Patient has >= grade 2 peripheral neuropathy, or grade 1 with pain on clinical examination during the screening period
Patient has >= grade 2 neuropathy, sensory, with or without pain, motor, or autonomic, on clinical examination during the screening period
Grade >= 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period
Patient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period
Patient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period
Patient has ? grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period
Patient has >= grade 2 peripheral neuropathy, or grade 1 with pain on clinical examination during the screening period
Patient has >= grade 2 peripheral neuropathy, or grade 1 with pain on clinical examination during the screening period
Peripheral neuropathy >= grade 2 on clinical examination or grade 1 with pain during the screening period
Has greater than or equal to (>=) Grade 2 peripheral neuropathy, or Grade 1 with pain on clinical examination during the screening period.
Patient has ? grade 2 peripheral neuropathy or grade 1 peripheral neuropathy with pain on clinical examination during the screening period
Peripheral neuropathy >= grade 3 on clinical examination or grade 2 with pain during the screening period
Patient has >= grade 3 peripheral neuropathy, or >= grade 2 with pain on clinical examination during the screening period
Peripheral neuropathy >= grade 2 on clinical examination, within 21 days of initiation of protocol therapy
Peripheral neuropathy >= grade 2 on clinical examination, within 21 days of initiation of protocol therapy
Patient has >= grade 1 peripheral neuropathy with pain on clinical examination during the screening period
Patient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period
Participant has >= grade 2 peripheral neuropathy on clinical examination within 21 days before initiation of protocol therapy
Patient has > grade 2 peripheral neuropathy on clinical examination during the screening period
Participant has >= grade 2 peripheral neuropathy on clinical examination within 21 days before initiation of protocol therapy
Patient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period
Patient has >= grade 2 peripheral neuropathy on clinical examination within 28 days of signing consent
Patient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period
Patient has grade 3 peripheral neuropathy or grade 2 with pain on clinical examination during the screening period
Patient has >= grade 3 peripheral neuropathy, or grade 2 peripheral neuropathy with pain on clinical examination during the screening period
Patient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period
Patient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period
Patient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening
Peripheral neuropathy >= grade 2 on clinical examination during the screening period
Patient with >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period
Patient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period
